Pulmatrix Q2 FY26 net loss narrows to $1.04 million; operating loss narrows to $1.05 million - PULM News | RalliesPulmatrix Q2 FY26 net loss narrows to $1.04 million; operating loss narrows to $1.05 million
P
PULM• Q2 results
- Pulmatrix posted a Q2 net loss of USD 1.04 million, narrowing from USD 1.55 million a year earlier.
- Loss per share narrowed to USD 0.29 from USD 0.42.
- General and administrative expense fell 32.05% to USD 1.04 million on lower software subscriptions, legal and patent costs, and merger activity.
- Cash and cash equivalents totaled USD 2.17 million at June 30, down from USD 4.09 million at Dec. 31.
- Form S-4 filed for the planned Eos SENOLYTIX merger, targeted to close in Q3; all clinical development remains on hold.
EAT
•
